Literature DB >> 15651433

Treating traumatic bleeding in a combat setting.

C Cloonan Clifford1.   

Abstract

Bleeding is clearly a major cause of morbidity and death after trauma. When bleeding is attributable to transection of major vessels, surgical repair is appropriate. Posttraumatic microvascular bleeding attributable to coagulopathy secondary to metabolic derangements, hypothermia, and depletion or dysfunction of cellular and protein components requires a different approach. Although transfusion of blood products may be necessary to replace the blood loss, it does not always correct the problem of microvascular bleeding. The type of injury, mode of care, and treatment objectives differ significantly for combat-wounded soldiers versus civilian trauma patients. Although hemorrhage is responsible for 50% of combat deaths, published information about coagulation monitoring among combat patients is very limited. These articles summarize the appropriate monitoring of hemostasis among combat trauma patients, review the unique nature of combat casualties and the medical system used to treat them, and discuss information available from civilian studies. Because the development of coagulopathy is relatively infrequent in the young, otherwise healthy, military population, the routine screening measures currently used are adequate to guide initial blood product administration. However, as new intravenous hemostatic agents are used for these patients, better laboratory measures will be required. Although hemorrhage is the leading cause of death for combat casualties, catastrophic hemorrhage is rarely a prehospital combat medical management problem because, when it occurs, it tends to cause death before medical care can be provided. In civilian environments, most seriously injured victims can be reached and transported by emergency medical services personnel within minutes; in combat, it often takes hours simply to transport casualties off the battlefield. In combat situations, even if the transport distances are small, the hazardous nature of the forward combat areas frequently prevents medical personnel from quickly reaching the wounded. Furthermore, whereas civilian blunt trauma victims may have a "golden hour," casualties with penetrating battlefield trauma often have only a "platinum 5 minutes." Because of the challenges of treating hemorrhage during combat, it is important for military medical personnel to understand their options for treating hemorrhage quickly and efficiently. These articles discuss the causes of posttraumatic microvascular bleeding and the potential treatment options for controlling catastrophic hemorrhage in combat areas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15651433     DOI: 10.7205/milmed.169.12s.8

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  13 in total

Review 1.  Tourniquet use in the civilian prehospital setting.

Authors:  C Lee; K M Porter; T J Hodgetts
Journal:  Emerg Med J       Date:  2007-08       Impact factor: 2.740

2.  Intravenous hemostatic nanoparticles increase survival following blunt trauma injury.

Authors:  Andrew J Shoffstall; Kristyn T Atkins; Rebecca E Groynom; Matthew E Varley; Lydia M Everhart; Margaret M Lashof-Sullivan; Blaine Martyn-Dow; Robert S Butler; Jeffrey S Ustin; Erin B Lavik
Journal:  Biomacromolecules       Date:  2012-10-08       Impact factor: 6.988

3.  Hemorrhage simulated by lower body negative pressure provokes an oxidative stress response in healthy young adults.

Authors:  Flora S Park; Victoria L Kay; Justin D Sprick; Alexander J Rosenberg; Garen K Anderson; Robert T Mallet; Caroline A Rickards
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-06

4.  Steroid-Loaded Hemostatic Nanoparticles Combat Lung Injury after Blast Trauma.

Authors:  William B Hubbard; Margaret M Lashof-Sullivan; Erin B Lavik; Pamela J VandeVord
Journal:  ACS Macro Lett       Date:  2015-03-23       Impact factor: 6.903

5.  Hemostatic Nanoparticles Improve Survival Following Blunt Trauma Even after 1 Week Incubation at 50 °C.

Authors:  Margaret Lashof-Sullivan; Mark Holland; Rebecca Groynom; Donald Campbell; Andrew Shoffstall; Erin Lavik
Journal:  ACS Biomater Sci Eng       Date:  2016-01-18

6.  Purification and characterization of human adrenomedullin binding protein-1.

Authors:  Xiaoling Qiang; Rongqian Wu; Youxin Ji; Mian Zhou; Ping Wang
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

Review 7.  Intravenous hemostats: challenges in translation to patients.

Authors:  Margaret Lashof-Sullivan; Andrew Shoffstall; Erin Lavik
Journal:  Nanoscale       Date:  2013-10-02       Impact factor: 7.790

8.  Tuning ligand density on intravenous hemostatic nanoparticles dramatically increases survival following blunt trauma.

Authors:  Andrew J Shoffstall; Lydia M Everhart; Matthew E Varley; Eric S Soehnlen; Adam M Shick; Jeffrey S Ustin; Erin B Lavik
Journal:  Biomacromolecules       Date:  2013-07-24       Impact factor: 6.988

9.  Remote ischemic preconditioning improves tissue oxygenation in a porcine model of controlled hemorrhage without fluid resuscitation.

Authors:  Gal Yaniv; Arik Eisenkraft; Lilach Gavish; Linn Wagnert-Avraham; Dean Nachman; Jacob Megreli; Gil Shimon; Daniel Rimbrot; Ben Simon; Asaf Berman; Matan Cohen; David Kushnir; Ruth Shaylor; Baruch Batzofin; Shimon Firman; Amir Shlaifer; Michael Hartal; Yuval Heled; Elon Glassberg; Yitshak Kreiss; S David Gertz
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.379

10.  A hybrid simulator model for the control of catastrophic external junctional haemorrhage in the military environment.

Authors:  Katarina Silverplats; Anders Jonsson; Lars Lundberg
Journal:  Adv Simul (Lond)       Date:  2016-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.